OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
301502$49.5856

Jiangsu Huayang Intelligent Equipment Co Ltd

Electrical Components & EquipmentVerified

Jiangsu Huayang's capital structure is characterized by a market cap of 2.83 billion CNY and a liquidity profile that could not be assessed due to missing balance-sheet inputs and no going-concern language in source documents. The firm's valuation snapshot shows a market price of 49.58 CNY per share, with no dilution risk identified in the current period. Profitability metrics are not available for direct comparison to industry medians, but the company's focus on high-margin segments like precision drug delivery devices and micro motor components suggests potential for strong returns. The absence of detailed margin data limits the ability to assess performance against industry benchmarks. The company's revenue is concentrated in three core segments: micro motor and component, precision drug delivery device, and diversified business. The micro motor and component segment serves home appliances, automobiles, and industrial control, while the precision drug delivery device segment targets medical applications such as dwarfism and diabetes. The diversified business includes products for home, medical, and office use. No geographic diversification is disclosed, with operations primarily in the domestic market. Growth trajectory is not quantified in the current data, but the company's product portfolio spans high-growth areas like medical devices and industrial automation. The outlook for the current fiscal year is not specified, and no numeric deltas are provided to assess revenue or margin changes. Risk factors include the inability to assess liquidity risk and the absence of detailed balance-sheet inputs. Dilution risk is currently low, with no adjustments applied to the valuation. However, the lack of going-concern language in source documents raises concerns about the completeness of financial disclosures. Recent events include the latest financial snapshot, which provides a baseline for valuation and risk assessment. No recent filings or transcripts are available to provide additional context on strategic direction or operational performance.

30-day price · 301502+33.27 (+77.9%)
Low$39.90High$77.00Close$76.00As of15 May, 00:00 UTC
Profile
CompanyJiangsu Huayang Intelligent Equipment Co Ltd
Ticker301502.SZ
SectorIndustrials
BusinessIndustrial Goods
Industry groupIndustrial Goods
IndustryElectrical Components & Equipment
AI analysis

Business. Jiangsu Huayang Intelligent Equipment Co Ltd designs, produces, and sells micro motors and application products for home appliances, automobiles, and industrial control, as well as precision drug delivery devices and diversified components for medical and office applications.

Classification. The company is classified under the Industrials sector, Industrial Goods business sector, and Electrical Components & Equipment industry with a confidence level of 0.92.

Jiangsu Huayang's capital structure is characterized by a market cap of 2.83 billion CNY and a liquidity profile that could not be assessed due to missing balance-sheet inputs and no going-concern language in source documents. The firm's valuation snapshot shows a market price of 49.58 CNY per share, with no dilution risk identified in the current period. Profitability metrics are not available for direct comparison to industry medians, but the company's focus on high-margin segments like precision drug delivery devices and micro motor components suggests potential for strong returns. The absence of detailed margin data limits the ability to assess performance against industry benchmarks. The company's revenue is concentrated in three core segments: micro motor and component, precision drug delivery device, and diversified business. The micro motor and component segment serves home appliances, automobiles, and industrial control, while the precision drug delivery device segment targets medical applications such as dwarfism and diabetes. The diversified business includes products for home, medical, and office use. No geographic diversification is disclosed, with operations primarily in the domestic market. Growth trajectory is not quantified in the current data, but the company's product portfolio spans high-growth areas like medical devices and industrial automation. The outlook for the current fiscal year is not specified, and no numeric deltas are provided to assess revenue or margin changes. Risk factors include the inability to assess liquidity risk and the absence of detailed balance-sheet inputs. Dilution risk is currently low, with no adjustments applied to the valuation. However, the lack of going-concern language in source documents raises concerns about the completeness of financial disclosures. Recent events include the latest financial snapshot, which provides a baseline for valuation and risk assessment. No recent filings or transcripts are available to provide additional context on strategic direction or operational performance.
Key takeaways
  • Jiangsu Huayang operates in high-growth industrial and medical equipment markets.
  • The company's product portfolio spans micro motors, drug delivery devices, and diversified components.
  • No liquidity risk is identified, but balance-sheet data is insufficient for a full assessment.
  • Revenue is concentrated in three core segments with no geographic diversification disclosed.
  • Dilution risk is currently low, but financial disclosures lack depth for comprehensive risk evaluation.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price$49.58
Market cap$2.83B
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Industrial Goods · cohort 13 companies
Metric301502Activity
Op margin9.4% medp25 9.4% · p75 9.4%
Net margin5.8% medp25 5.8% · p75 5.8%
Gross margin26.9% medp25 26.9% · p75 26.9%
R&D / revenue2.0% medp25 1.6% · p75 3.0%
CapEx / revenue2.4% medp25 1.6% · p75 3.3%
Debt / equity106.4% medp25 106.4% · p75 106.4%
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-07 19:07 UTC#09073246
Market quoteclose CNY 49.58 · shares 0.06B diluted
no public URL
2026-05-04 10:27 UTC#ca316ca7
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 10:28 UTCJob: d8c60aae